Rising US scrutiny on clinical trials could threaten China’s biotech advantage: analysts
China’s edge in fast, cost-effective early clinical trials has propelled its emergence as a global biopharmaceutical powerhouse, but there is a risk that the United States could take steps to curb that advantage, according to analysts. US lawmakers and officials at the Food and Drug Administration (FDA) have raised the alarm about American pharmaceutical companies’ growing reliance on conducting…
We haven't written up this one. South China Morning Post has the full story — the link below goes straight to it.
